Aurora kinases: New targets for cancer therapy

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 6869-6875

  Carvajal, Richard D ^a   Tse, Archie ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT 9283; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; AZD 1152; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; HESPERADIN; MLN 8054; MP 235; MP 529; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PHA 680632; PHA 739358; R 763; SNS 314;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MITOSIS; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 33845743957     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1405     Document Type: Review

References (50)

1. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65.
2. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation [see comment]. Nat Genet 1998;20:189-93.
3. Tatsuka M, Katayama H, Ota T, et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998;58:4811-6.
4. Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002;62:5168-77.
5. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003; 161:281-94.
6. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-80.
7. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo [see comment]. Nat Med 2004;10:262-7.
8. Soncini C, Carpinelli P, Gianellini L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006;12:4080-9.
9. Berdnik D, Knoblich JA. Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol 2002;12:640-7.
10. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells [see comment]. Cell 2003;114:585-98.
11. 2-M transition. J Cell Sci 2004; 117:2523-31.
12. Marumoto T, Honda S, Hara T, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-95.
13. Kufer TA, Sillje HH, Korner R, Gruss OJ, Meraldi P, Nigg EA. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 2002; 158:617-23.
14. Eyers PA, Erikson E, Chen LG, Maller JL. A novel mechanism for activation of the protein kinase Aurora A. Curr Biol 2003;13:691-7.
15. Kunitoku N, Sasayama T, Marumoto T, et al. CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Dev Cell 2003;5:853-64.
16. Tsai MY, Wiese C, Cao K, et al. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat Cell Biol 2003;5:242-8.
17. Liu Q, Kaneko S, Yang L, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279:52175-82.
18. Sakai H, Urano T, Ookata K, et al. MBD3 and HDAC1, two components of the NuRD complex, are localized at Aurora-A-positive centrosomes in M phase. J Biol Chem 2002;277:48714-23.
19. 2 to M transition. J Biological Chem 2004;279:19643-8.
20. Castro A, Vigneron S, Bernis C, Labbe JC, Prigent C, Lorca T. The D-Box-activating domain (DAD) is a new proteolysis signal that stimulates the silent D-Box sequence of Aurora-A. EMBO Rep 2002;3:1209-14.
21. Honda K, Mihara H, Kato Y, et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 2000;19:2812-9.
22. Marumoto T, Zhang D, Saya H. Aurora-A: a guardian of poles. Nat Rev Cancer 2005;5:42-50.
23. Giet R, Glover DM. Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol 2001;152:669-82.
24. Goto H, Yasui Y, Kawajiri A, et al. Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J Biol Chem 2003; 278:8526-30.
25. Murata-Hori M, Wang YL. The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis [see comment]. Curr Biol 2002; 12:894-9.
26. Zeitlin SG, Shelby RD, Sullivan KF. CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J Cell Biol 2001; 155:1147-57.
27. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003;14:3325-41.
28. Sessa F, Mapelli M, Ciferri C, et al. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell 2005;18:379-91.
29. Crosio C, Fimia GM, Loury R, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002;22:874-85.
30. Stewart S, Fang G. Destruction box-dependent degradation of aurora B is mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer Res 2005;65:8730-5.
31. Lan W, Zhang X, Kline-Smith SL, et al. Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Curr Biol 2004;14:273-86.
32. Tanaka TU, Rachidi N, Janke C, et al. Evidence that the Ipl1-15 (Aurora kinase-INCENP) complex promotes chromosome bi-orientation by altering kinetochore-spindle pole connections. Cell 2002;108:317-29.
33. Musacchio A, Hardwick KG. The spindle checkpoint: structural insights into dynamic signalling. Nat Rev Mol Cell Biol 2002;3:731-41
34. Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell 2002;13:755-66.
35. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
36. Gritsko TM, Coppola D, Paciga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-6.
37. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002; 21:483-92.
38. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3:51-62.
39. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995;81:95-105.
40. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005;65:2899-905.
41. Severson AF, Hamill DR, Carter JC, Schumacher J, Bowerman B. The aurora-related kinase AIR-2 recruits ZEN-4/CeMKLP1 to the mitotic spindle at metaphase and is required for cytokinesis. Curr Biol 2000;10:1162-71.
42. Kallio MJ, McCleland ML, Stukenberg PT, Gorbsky GJ. Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis [see comment]. Curr Biol 2002;12:900-5.
43. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-6.
44. Rubin E, Shapiro G, Stein M, et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients [abstract 3009]. Proc Am Soc Clin Oncol 2006;24:123s.
45. Hoar HM, Wysong DR, Ecsedy JA. MLN8054 selectively inhibits Aurora A over Aurora B in cultured human tumor cells [abstract C40]. Proc AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2005.
46. Huck J, Zhang M, Burenkova O, Connolly K, Manfredi M, Meetze K. Preclinical antitumor activity with MLN8054, a small molecule Aurora A kinase inhibitor [abstract 4698]. Proc Am Assoc Cancer Res 2006;47:1104.
47. Nair JS, Tse A, Keen N, Schwartz GK. A novel aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with chemotherapy [abstract 9568]. Proc Am Soc Clin Oncol 2004;23:848.
48. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006; 66:7668-77.
49. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, highly potent Aurora kinase inhibitor, with selectivity for Aurora kinase B, induces pharmacodynamic effects and significant growth inhibition in human tumor xenograft models [abstract B214]. Proc AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2005(183).
50. Schellens J, Boss D, Witteveen P, et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152 [abstract 3008]. Proc Am Soc Clin Oncol 2006;24:122s.